Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Hematopoietic and Lymphatic System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Hematopoietic and Lymphatic System Neoplasm

Cancer Family

Hematopoietic and Lymphatic System Neoplasm

CI-CAN-00000022Explore in graph →

Non-malignant4,304 active trials98 approved drugs1,010 evidence items

NCIt: C35813

Overview
Statistics
Survival
Genomics60
Variants & evidence1010
Drugs99
Trials18827
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (736)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 626–650 of 736 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.
· Mol Genet Genomic Med · 2015 · PMID 25802883 · validated civic_curation pubmed
Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions.
· Eur J Hum Genet · 2008 · PMID 18478040 · validated civic_curation pubmed
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
· Cancer Res · 2005 · PMID 15930265 · validated civic_curation pubmed
Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.
· Pediatr Blood Cancer · 2017 · PMID 27860260 · validated civic_curation pubmed
NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.
· Haematologica · 2016 · PMID 26681761 · validated civic_curation pubmed
Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.
· Eur J Haematol · 2014 · PMID 24215620 · validated civic_curation pubmed
Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia.
· Br J Haematol · 2011 · PMID 21391972 · validated

Showing 626–650 of 736 publications

← Previous
1
…
25
26
27
…
30
Next →

civic_curation

Identification of novel kinase fusion transcripts in paediatric B cell precursor acute lymphoblastic leukaemia with IKZF1 deletion.

· Br J Haematol · 2015 · PMID 26404892 · validated civic_curation pubmed

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.

· Blood · 2020 · PMID 32232486 · validated civic_curation pubmed

Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.

· Leukemia · 2004 · PMID 14737077 · validated civic_curation pubmed

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.

· Br J Haematol · 2019 · PMID 31234236 · validated civic_curation pubmed

The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1.

· Genes Chromosomes Cancer · 2008 · PMID 18205209 · validated civic_curation pubmed

A new partner gene fused to ABL1 in a t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.

· Leukemia · 2007 · PMID 17541395 · validated civic_curation pubmed

RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic Leukemia.

· Case Rep Hematol · 2015 · PMID 26600955 · validated civic_curation pubmed

Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).

· Leuk Lymphoma · 2017 · PMID 27855558 · validated civic_curation pubmed

The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene.

· Blood · 1989 · PMID 2499362 · validated civic_curation pubmed

An 8-year-old girl with secondary histiocytic sarcoma with BRAFV600 mutation following T-cell acute lymphoblastic leukemia demonstrating stable disease for 3 years on dabrafenib and trametinib - a case report and literature review.

· BMC Pediatr · 2025 · PMID 40057687 · validated civic_curation pubmed

BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.

· Lab Med · 2019 · PMID 30938769 · validated civic_curation pubmed

SNX2-ABL1-positive acute lymphoblastic leukemia possibly has a poor prognosis.

· Leuk Lymphoma · 2017 · PMID 28278724 · validated civic_curation pubmed

Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with a t(9;10)(q34;q22.3) translocation.

· Leukemia · 2008 · PMID 18007576 · validated civic_curation pubmed

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.

· Cancer Sci · 2021 · PMID 33492746 · validated civic_curation pubmed

Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.

· Oncogene · 2002 · PMID 12483530 · validated civic_curation pubmed

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

· Blood · 2010 · PMID 20739657 · validated civic_curation pubmed

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

· Mol Cancer Ther · 2007 · PMID 18089725 · validated civic_curation pubmed

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

· Cell · 2011 · PMID 21889194 · validated civic_curation pubmed